查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1901507

發燒性嗜中性白血球減少症市場：依病因、治療方法、危險因子、診斷方法、國家及地區分類－全球產業分析、市場規模、市場佔有率及2025-2032年預測

Febrile Neutropenia Market, By Etiology, By Treatment, By Risk Factors, By Diagnostic Methods, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 355 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年發燒性嗜中性白血球減少症市場規模為 107.8945 億美元，從 2025 年到 2032 年以 4.2% 的複合年成長率成長。

發燒性嗜中性白血球減少症是指嗜中性白血球數異常低的患者出現快速發燒，最常見的原因是化療引起的骨髓抑制。這種情況屬於高風險醫療急症，需要迅速採取抗菌干預措施以預防嚴重感染和敗血症。隨著腫瘤病例的增加和臨床醫生優先考慮風險分層管理方案，全球市場正在蓬勃發展。長效粒細胞集落刺激因子（G-CSF）製劑、快速診斷試劑盒和感染控制演算法的進步正在顯著推動臨床應用。然而，前景並非一片光明——高昂的生物製劑價格、抗菌藥物抗藥性和報銷障礙仍然限制著藥物的公平獲取，尤其是在資源匱乏的地區。即便如此，隨著精準支持治療模式、即時診斷和人工智慧驅動的感染預測工具從試點階段走向主流應用，該領域仍蘊藏著巨大的機會。這些創新可望重新定義發燒性嗜中性白血球減少症的治療，為更安全、更快速、更具成本效益的病患治療效果奠定基礎。

發燒性嗜中性白血球減少症市場－市場動態

全球癌症負擔日益加重

世界衛生組織（WHO）指出，全球癌症負擔日益加重是發燒性嗜中性白血球減少症（FN）市場成長的最重要促進因素。世衛組織表示，由於老年人口數量不斷增加以及人們暴露於其他風險因素（例如吸煙、肥胖和污染）的程度加深，預計未來全球新增癌症病例數將成為一個重要因素。隨著越來越多的患者接受骨髓抑制性化療和/或其他類型的侵襲性癌症治療，這些患者中性粒細胞減少症的發生率將會上升，進而導致FN病例的增加。數據顯示，接受化療的患者中，發燒性嗜中性白血球減少症的發生率高達30%。因此，隨著癌症患者數量的持續成長，對FN管理解決方案（包括預防性治療和快速診斷）的需求也將隨之成長。由此可見，癌症患者數量的增加是FN市場成長的主要動力。

發燒性嗜中性白血球減少症市場區隔分析：

全球發燒性嗜中性白血球減少症市場按病因、治療、風險因子、診斷方法和地區進行細分。

從病因學角度來看，發燒性嗜中性白血球減少症可分為革蘭氏陰性菌感染、革蘭氏陽性菌感染、黴菌感染和病毒感染。在發燒性嗜中性白血球減少症中，革蘭氏陰性菌感染被認為是此併發症的主要臨床原因之一，因為它們毒性強且對抗生素的抗藥性日益增強。這些細菌包括大腸桿菌、克雷伯氏菌和綠膿桿菌，它們仍然是主要的致病菌。根據美國疾病管制與預防中心的資料，革蘭氏陰性菌感染佔所有醫療相關血流感染的40%以上，這表明對於免疫系統受損的患者（例如腫瘤患者），控制這些感染至關重要。因此，這些感染迅速發展為敗血症，且死亡風險較高，需要立即使用廣效抗生素進行干預。腸桿菌科細菌產生的超廣譜BETA-內醯胺酶（ESBLs）的出現，使這些感染的治療更加複雜。因此，人們越來越需要開發新型抗生素、快速診斷方法，並在發燒性嗜中性白血球減少症（FN）的治療中應用精準的抗菌藥物管理策略，以幫助控制這些病原體的流行。

根據美國傳染病學會 (IDSA) 和美國國家綜合癌症網路 (NCCN) 的指南，發燒性嗜中性球減少症 (FN) 的治療幾乎完全依賴經驗性抗生素治療，因為需要在檢測到發燒後 60 分鐘內開始使用抗菌藥物。所謂的「黃金一小時」至關重要，因為 FN 患者病情可能迅速惡化為感染性休克。用於治療 FN 患者的主要抗生素包括廣譜 BETA-內醯胺類抗生素、碳青黴烯類抗生素和抗假單胞菌抗生素。抗菌藥物抗藥性的日益成長帶來的全球健康威脅促使醫院採用聯合療法、廣譜抗生素和抗菌藥物管理方案；這部分治療仍然是 FN 患者治療的主要手段，並將隨著速效靜脈製劑和高靈敏度病原體檢測技術的不斷發展而持續改進。

發燒性嗜中性白血球減少症市場—地理洞察

北美發燒性嗜中性白血球減少症治療市場價值高，但已趨於成熟。造成這種情況的原因之一是該地區癌症患者數量龐大；由於能夠獲得強化化療，目前北美有大量癌症患者正在接受治療。此外，該地區癌症病例記錄也十分豐富；美國、加拿大和墨西哥是2022年新增癌症病例最多的國家（約290萬例）。據估計，到2024年，美國將通報約200萬例新增癌症病例，並通報超過61.1萬例癌症死亡病例。由於這些患者接受骨髓抑制療法，且大多數患者同時接受支持性發燒性嗜中性白血球減少症預防治療，因此有大量發燒性嗜中性白血球減少症高風險族群。鑑於醫院已建立完善的發燒性中性粒細胞減少症（FN）治療體系，醫療服務提供者嚴格遵循美國感染病學會（IDSA）和美國國家綜合癌症網路（NCCN）的FN管理指南，以及粒細胞集落刺激因子（G-CSF）生物類似藥和廣譜靜脈注射抗生素的迅速減少，我們能夠處理大量病例，及早干預，並為早發熱性干預，並為早發性治療的在美國，影響發燒性嗜中性白血球減少症治療的因素有很多，包括：抗菌藥物抗藥性日益嚴重的趨勢、以價值為導向的醫療模式的不斷發展，以及在急診和腫瘤科等環境中，利用快速分子診斷技術對低風險患者進行風險分層和門診FN管理的日益普及。

美國發燒性嗜中性白血球減少症市場—國家概況

美國是北美治療發燒性嗜中性白血球減少症（FN）醫療產品的最大市場，其癌症發生率（按年齡調整後）一直位居世界前列（每年每10萬人中有367例）。許多患者接受強化多藥化療、幹細胞移植以及標靶抗癌藥物和免疫治療方案等新型生物製劑/療法，這意味著存在大量持續存在的發燒性嗜中性白血球減少症高風險患者。美國癌症協會估計，到2024年，美國將新增約200萬例癌症病例，並有約611,720例癌症死亡病例。因此，對於FN患者而言，獲得明確的FN預防性治療、適當的經驗性/抗菌治療以及先進的支持性護理的需求仍然十分旺盛。除了上述好處外，美國市場還受益於健康保險公司對粒細胞集落刺激因子（G-CSF）和昂貴注射劑的高額報銷，以及膿毒症檢測自動化預警系統的廣泛應用和抗菌藥物管理項目的大力發展和實施。此外，還存在成本和可及性問題，包括基於種族、地理位置和醫院感染等因素造成的醫療服務獲取差異，這些問題推動了門診發燒性中性粒細胞減少症（FN）管理和口服降階治療方案的創新和應用，以及預測分析在治療早期對高風險患者進行分診的應用。

目錄

第1章：發燒性嗜中性白血球減少症市場概覽

  • 研究範圍
  • 市場估算年份

第2章：執行概要

  • 市集
  • 競爭洞察

第3章：發燒性嗜中性白血球減少症主要市場趨勢

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場未來趨勢

第4章：發燒性嗜中性白血球減少症產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景分析
  • 規範架構分析

第5章：發燒性嗜中性白血球減少症市場：地緣政治緊張局勢升級的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：發燒性嗜中性白血球減少症市場概況

  • 發燒性嗜中性白血球減少症市佔率分析，2024 年
  • 主要製造商細分數據
    • 知名球員分析
    • 新興參與者分析

第7章：發燒性嗜中性白血球減少症市場：依病因分類

  • 概述
    • 細分市場佔有率分析：依病因學
    • 革蘭氏陰性菌
    • 革蘭氏陽性菌
    • 黴菌感染
    • 病毒感染

第8章：發燒性嗜中性白血球減少症市場：依治療方式分類

  • 概述
    • 細分市場佔有率分析：依治療方式
    • 經驗性抗生素治療
    • 標靶抗生素治療
    • 支持性護理

第9章：發燒性嗜中性白血球減少症市場：依危險因子分類

  • 概述
    • 細分市場佔有率分析：依風險因素分類
    • 化療引起的嗜中性白血球減少症
    • 移植相關性嗜中性白血球減少症
    • 遺傳性疾病

第10章：發燒性嗜中性白血球減少症市場：依診斷方法分類

  • 概述
    • 細分市場佔有率分析：透過診斷方法
    • 血液培養
    • 影像檢查
    • 骨髓穿刺

第11章：發燒性嗜中性白血球減少症市場：依地域分類

  • 介紹
  • 北美洲
    • 概述
    • 北美主要製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲主要製造商
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • その他
  • 亞太地區
    • 概述
    • 亞太地區主要製造商
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • その他
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • その他
  • 中東和非洲
    • 概述
    • 中東和非洲的主要製造商
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • その他

第12章：主要供應商分析：發燒性嗜中性白血球減少症產業

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • Amneal Pharmaceuticals, Inc.
    • AstraZeneca
    • Aurobindo Pharma Limited
    • Bayer
    • BeyondSpring Inc.
    • Biocon Biologics Ltd.
    • Biogen
    • BristolMyers Squibb
    • Celgene
    • Cellerant Therapeutics, Inc.
    • Coherus BioSciences, Inc.
    • Eli Lilly and Company
    • Fresenius Kabi
    • G1 Therapeutics, Inc.
    • Gedeon Richter Plc.
    • GlaxoSmithKline
    • Hanmi Pharmaceutical Co., Ltd.
    • Intas Pharmaceuticals Ltd.
    • Johnson Johnson
    • Kyowa Kirin Co., Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Partner Therapeutics, Inc.
    • Pfizer Inc.
    • Roche
    • Sanofi
    • Spectrum Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Others

第13章：全面展望

簡介目錄
Product Code: ANV5802

Febrile Neutropenia Market size was valued at US$ 10,789.45 Million in 2024, expanding at a CAGR of 4.2% from 2025 to 2032.

Febrile neutropenia refers to a rapid-onset fever occurring in patients with abnormally low neutrophil counts, most commonly triggered by chemotherapy-induced bone marrow suppression. This condition represents a high-acuity medical emergency, demanding swift antimicrobial intervention to prevent severe infections and sepsis. The global market is gaining momentum as oncology caseloads rise and clinicians prioritize risk-stratified management protocols. Advancements in long-acting G-CSF formulations, rapid diagnostic panels, and infection-control algorithms are creating measurable shifts in clinical adoption. Yet, the landscape isn't all sunshine-elevated biologic drug prices, antimicrobial resistance, and reimbursement barriers continue to constrain equitable access, especially in resource-limited settings. Even so, the sector is ripe with opportunity as precision supportive-care models, point-of-care diagnostics, and AI-enabled infection-prediction tools move from pilot to mainstream. These innovations are poised to redefine febrile neutropenia management, setting the stage for safer, faster, and more cost-effective patient outcomes.

Febrile Neutropenia Market- Market Dynamics

Rising Global Burden of Cancer

The increasing global cancer burden is the most significant growth catalyst for the febrile neutropenia (FN) market, according to the World Health Organization (WHO), who states that the number of new cancer cases globally is expected to be a significant factor in the future due to increasing numbers of elderly individuals as well as individuals being exposed to additional risk factors (e.g. tobacco use; obesity and pollution). As a larger number of individuals undergo myelosuppressive chemotherapy and/or other types of aggressive cancer treatments, those individuals will experience a rise in incidence of neutropenia which leads to an increase in FN. Data indicates that febrile neutropenia occurs in as many as 30% of patients undergoing chemotherapy. The result is that as the amount of cancer patients continues to grow, the need for FN management solutions (including prophylactic treatments and rapid diagnostics) will grow along with it. Thus, the increase in cancer patient volumes is the main growth driver for the FN marketplace.

Febrile Neutropenia Market- Segmentation Analysis:

The Global Febrile Neutropenia Market is segmented on the basis of Etiology, Treatment, Risk Factors, Diagnostic Methods, and Region.

In terms of etiology, the febrile neutropenia market is divided into gram-negative bacteria, gram-positive bacteria, fungal infections, viral infections. In febrile neutropenia, gram-negative bacteria are considered one of the main clinical causes of this complication because of their high levels of virulence and increasing levels of resistance to antibiotics. Some of these organisms include Escherichia coli, Klebsiella, and Pseudomonas Aeruginosa and they continue to be the primary culprits. Gram-negative infections represent more than 40% of all healthcare-associated bloodstream infections according to data from the Center for Disease Control and Prevention, indicating the importance of managing these infections in patients with compromised immune systems (i.e., oncology patients). Therefore, their rapid advancement into sepsis coupled with an elevated risk of death from these infections warrants an immediate intervention with broad-spectrum antibiotics. The emergence of Beta-lactamase producing Extended Spectrum Beta-Lactamases (ESBLs) from Enterobacterales has added an additional level of complexity to the management of these infections. Therefore, there continues to be an increasing demand for the development of new antibiotics, rapid diagnostics, and the use of precision antimicrobial stewardship strategies in FN settings to help control the rise of these organisms.

Based on treatment, treatment of febrile neutropenia (FN) is almost entirely based on empirical antibiotic therapy because of the need to begin antimicrobials within 60 minutes of detecting fever, as outlined by the Infectious Disease Society of America (IDSA) and National Comprehensive Cancer Network (NCCN) guidelines. The so-called "golden hour" is imperative as FN patients can deteriorate rapidly into septic shock. The principal antibiotics utilized to treat FN patients include broad-spectrum B-lactams, carbapenems and anti-pseudomonal antibiotics. The global health threat posed by the rise in antimicrobial resistance has prompted hospitals to use combination therapy, extended-spectrum agents, and stewardship programs; this segment of care remains the mainstay of treatment for FN patients and will continue to evolve with ongoing developments in the availability of fast-acting intravenous (IV) formulations and high-sensitivity pathogen detection technologies.

Febrile Neutropenia Market- Geographical Insights

The febrile neutropenia treatment market in North America is high-value but mature. One of the reasons for this is because of the high levels of cancer being treated by this market; there's a very large number of cancer patients that are currently being treated in North America due to access to intensive chemotherapy. Additionally, there have been many cancer cases recorded in this geographical area; the United States, Canada, and Mexico have been identified as the leading nations in terms of new cancer cases in 2022 (approximately 2.9 million new cases). It is estimated that in 2024, there will be around 2.0 million new cases reported and over 611,000 deaths reported from cancer in the United States. Because these patients receive myelosuppressive therapies with the majority having supportive FN prophylaxis, there is a large pool of people at risk for febrile neutropenia. Given the establishment of hospitals with well-developed systems for treating FN, the strict adherence by healthcare providers to the IDSA and guidelines of the National Comprehensive Cancer Network (NCCN) for FN management, and the rapid acceptance of G-CSF biosimilars and broad-spectrum IV antibiotics, it is possible to print a high volume of cases, intervene early, and provide aggressive treatment to patients with febrile neutropenia. There are several factors impacting the treatment of febrile neutropenia in the United States, including; the rising trend of increasing antimicrobial resistance, the growing development of value-based care models, and the growing use of risk stratification pathways and outpatient management of FN in lower-risk patients utilizing rapid molecular diagnostics in emergency and oncology settings.

United States Febrile Neutropenia Market- Country Insights

The United States is the largest market in North America for medical products treating febrile neutropenia and continues to have one of the highest age-adjusted rates of cancer incidence (367 cases per 100,000) reported annually in the world. The fact that many patients receive intensive multi-drug chemotherapy, stem cell transplants, and new biologics/treatments with targeted anti-cancer drugs and immunotherapeutic regimens means there is a steady and persistent supply of patients who are at risk for developing febrile neutropenia. The American Cancer Society estimates that there will be approximately 2 million new cases of cancer and approximately 611,720 cancer deaths in the U.S. in 2024. Therefore, there continues to be a very strong demand for clear access to FN prophylactic therapies, appropriate empirical/antimicrobial therapy, and advanced supportive care to patients with FN. In addition to the above-mentioned benefits, the U.S. market is also experiencing high levels of reimbursement provided by health insurance companies for the use of G-CSF and expensive injectable products, as well as broad utilization of automated alert systems for sepsis detection and extensive development and use of antimicrobial stewardship programs. There are also cost and access issues, including disparities in access to care based on race, geographic location, and hospital-acquired infections, which are driving innovation and adoption of the use of outpatient FN management and oral step-down regimens, as well as the introduction of predictive analytics to triage higher-risk patients earlier in the treatment process.

Febrile Neutropenia Market- Competitive Landscape:

The landscape for Febrile Neutropenia is characterized by competition between a number of companies, including Amneal Pharmaceuticals, Inc., AstraZeneca, Aurobindo Pharma Limited, Bayer, BeyondSpring Inc., Biocon Biologics Ltd., Biogen, Bristol Myers Squibb, Celgene Cellerant Therapeutics, Coherus BioSciences, Eli Lilly, Fresenius Kabi, G1 Therapeutics, Gedeon Richter, GSK, Hanmi, Intas Pharmaceuticals, Johnson & Johnson, Kyowa Kirin, Merck & Co., Novartis AG, Partner Therapeutics, Pfizer Inc, Roche, Sanofi, Spectrum Pharmaceuticals, Teva, and Viatris Inc. The competition will primarily be around G-CSFs and G-CSF biosimilars, long acting pegfilgrastim (peg G-CSF or filgrastim) formulations and novel myeloprotective agents that are also part of general oncology portfolios. Biocon Biologics developed and commercialized pegfilgrastim biosimilar Fulphila with Viatris. Fulphila is approved in the U.S., European Union (EU), Canada, and other countries and is intended to decrease the length of time patients with neutropenia are at risk for febrile neutropenia, which provides an opportunity for biosimilars to create both price and access competition. Coherus expanded Pegfilgrastim franchise with UDENYCA and its on-body injection device, before choosing to sell the franchise to Intas/Accord while moving towards focus on Immuno-oncology. BeyondSpring advanced its myeloprotective candidate plinabulin, received Breakthrough Therapy designations for use in chemotherapy related neutropenia, but was ultimately issued an FDA complete response letter requesting additional data. G1 therapeutics' trilaciclib (COSELA) was the first myeloprotective therapy to have received FDA approval for prevention of chemotherapy associated myelosuppression. In this environment, the aforementioned larger pharmaceutical players (Pfizer, Merck, Novartis, Roche, Sanofi, J&J, AstraZeneca, Bayer, Lilly, and Teva) are incorporating FN-risk-reduction approaches into their Immunotherapy and Targeted Therapy regimens, pursuing alliances with biosimilar partners, and utilizing real-world evidence to maintain market shares in both mature and emerging markets, thereby making competition increasingly driven by the need for innovation and access..

Recent Developments:

In August 2025, Intas/Accord announced successful acquisition of UDENYCA, strengthening its biosimilar portfolio and positioning itself as a "global pegfilgrastim supplier." UDENYCA remains indicated to reduce infection incidence (i.e. FN risk) in non-myeloid cancer patients receiving myelosuppressive chemotherapy. The deal transferred not only the product, but also relevant Coherus teams responsible for sales, supply, manufacturing and quality.

In September 2025, Amgen (US) launched a new digital platform aimed at improving patient engagement and adherence to treatment protocols for febrile neutropenia. This initiative reflects Amgen's focus on digital transformation and its recognition of the importance of patient-centric approaches in enhancing treatment outcomes. By leveraging technology, Amgen is likely to strengthen its competitive edge and foster deeper connections with healthcare providers and patients alike.

In August 2025, Roche (CH) announced a significant collaboration with a leading biotechnology firm to develop a novel treatment for febrile neutropenia, which is expected to enter clinical trials in early 2026. This strategic move underscores Roche's commitment to innovation and its proactive approach to addressing unmet medical needs in the oncology space. By aligning with a biotechnology partner, Roche not only enhances its research capabilities but also positions itself to potentially capture a larger market share in the febrile neutropenia segment.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FEBRILE NEUTROPENIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca
  • Aurobindo Pharma Limited
  • Bayer
  • Beyond Spring Inc.
  • Biocon Biologics Ltd.
  • Biogen
  • BristolMyers Squibb
  • Celgene
  • Cellerant Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Eli Lilly and Company
  • Fresenius Kabi
  • G1 Therapeutics, Inc.
  • Gedeon Richter Plc.
  • GlaxoSmithKline
  • Hanmi Pharmaceutical Co., Ltd.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Partner Therapeutics, Inc.
  • Pfizer Inc.
  • Roche
  • Sanofi
  • Spectrum Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Others

GLOBAL FEBRILE NEUTROPENIA MARKET, BY ETIOLOGY- MARKET ANALYSIS, 2019 - 2032

  • Gram-Negative Bacteria
  • Gram-Positive Bacteria
  • Fungal Infections
  • Viral Infections

GLOBAL FEBRILE NEUTROPENIA MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Empirical Antibiotic Therapy
  • Targeted Antibiotic Therapy
  • Supportive Care

GLOBAL FEBRILE NEUTROPENIA MARKET, BY RISK FACTORS- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy-Induced Neutropenia
  • Transplant-Related Neutropenia
  • Genetic Disorders

GLOBAL FEBRILE NEUTROPENIA MARKET, BY DIAGNOSTIC METHODS- MARKET ANALYSIS, 2019 - 2032

  • Blood Cultures
  • Imaging Tests
  • Bone Marrow Aspiration

GLOBAL FEBRILE NEUTROPENIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Febrile Neutropenia Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Febrile Neutropenia Market Snippet by Etiology
    • 2.1.2. Febrile Neutropenia Market Snippet by Treatment
    • 2.1.3. Febrile Neutropenia Market Snippet by Risk Factors
    • 2.1.4. Febrile Neutropenia Market Snippet by Diagnostic Methods
    • 2.1.5. Febrile Neutropenia Market Snippet by Country
    • 2.1.6. Febrile Neutropenia Market Snippet by Region
  • 2.2. Competitive Insights

3. Febrile Neutropenia Key Market Trends

  • 3.1. Febrile Neutropenia Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Febrile Neutropenia Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Febrile Neutropenia Market Opportunities
  • 3.4. Febrile Neutropenia Market Future Trends

4. Febrile Neutropenia Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Febrile Neutropenia Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Febrile Neutropenia Market Landscape

  • 6.1. Febrile Neutropenia Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Febrile Neutropenia Market - By Etiology

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Etiology, 2024 & 2032 (%)
    • 7.1.2. Gram-Negative Bacteria
    • 7.1.3. Gram-Positive Bacteria
    • 7.1.4. Fungal Infections
    • 7.1.5. Viral Infections

8. Febrile Neutropenia Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
    • 8.1.2. Empirical Antibiotic Therapy
    • 8.1.3. Targeted Antibiotic Therapy
    • 8.1.4. Supportive Care

9. Febrile Neutropenia Market - By Risk Factors

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Risk Factors, 2024 & 2032 (%)
    • 9.1.2. Chemotherapy-Induced Neutropenia
    • 9.1.3. Transplant-Related Neutropenia
    • 9.1.4. Genetic Disorders

10. Febrile Neutropenia Market - By Diagnostic Methods

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Diagnostic Methods, 2024 & 2032 (%)
    • 10.1.2. Blood Cultures
    • 10.1.3. Imaging Tests
    • 10.1.4. Bone Marrow Aspiration

11. Febrile Neutropenia Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Febrile Neutropenia Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Febrile Neutropenia Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Febrile Neutropenia Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Febrile Neutropenia Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Febrile Neutropenia Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Febrile Neutropenia Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Amneal Pharmaceuticals, Inc.
    • 12.2.2. AstraZeneca
    • 12.2.3. Aurobindo Pharma Limited
    • 12.2.4. Bayer
    • 12.2.5. BeyondSpring Inc.
    • 12.2.6. Biocon Biologics Ltd.
    • 12.2.7. Biogen
    • 12.2.8. BristolMyers Squibb
    • 12.2.9. Celgene
    • 12.2.10. Cellerant Therapeutics, Inc.
    • 12.2.11. Coherus BioSciences, Inc.
    • 12.2.12. Eli Lilly and Company
    • 12.2.13. Fresenius Kabi
    • 12.2.14. G1 Therapeutics, Inc.
    • 12.2.15. Gedeon Richter Plc.
    • 12.2.16. GlaxoSmithKline
    • 12.2.17. Hanmi Pharmaceutical Co., Ltd.
    • 12.2.18. Intas Pharmaceuticals Ltd.
    • 12.2.19. Johnson Johnson
    • 12.2.20. Kyowa Kirin Co., Ltd.
    • 12.2.21. Merck & Co., Inc.
    • 12.2.22. Novartis AG
    • 12.2.23. Partner Therapeutics, Inc.
    • 12.2.24. Pfizer Inc.
    • 12.2.25. Roche
    • 12.2.26. Sanofi
    • 12.2.27. Spectrum Pharmaceuticals, Inc.
    • 12.2.28. Teva Pharmaceutical Industries Ltd.
    • 12.2.29. Viatris Inc.
    • 12.2.30. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us